Compare · head to head
Dottikon vs Novartis
Novartis ranks higher overall — 360 rank 38 vs 34.
Novartis leads on Value (51 vs 28) and Quality (65 vs 36). Dottikon leads on Growth (60 vs 37), Safety (61 vs 44) and Sentiment (49 vs 39).
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | Switzerland | Switzerland |
| Sector | Health Care | Health Care |
| Industry | Pharmaceuticals | Pharmaceuticals |
| Size | Medium | XX-Large |
| ISIN | CH0582581713 | CH0012005267 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | ||
| Ranks | ||
| 360 | 34 | 38 |
| Value | 28 | 51 |
| Quality | 36 | 65 |
| Growth | 60 | 37 |
| Safety | 61 | 44 |
| Sentiment | 49 | 39 |
| Quality details | ||
| Profitability | 38 | 76 |
| Cash Truth | 33 | 55 |
Dottikon vs GSKDottikon vs Avadel PharmaceuticalsDottikon vs VirbacDottikon vs Cohance LifesciencesAdd a third stock →
Full analyses: Dottikon · Novartis
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100